Pre-analytical stage for biomarker assessment in breast cancer: 2014 update of the GEFPICS' guidelines in France

被引:12
|
作者
MacGrogan, Gaetan [1 ]
Mathieu, Marie-Christine [1 ]
Poulet, Bruno [1 ]
Penault-Llorca, Frederique [1 ]
Vincent-Salomon, Anne [1 ]
Roger, Pascal [1 ]
Treilleux, Isabelle [1 ]
Valent, Alexander [1 ]
Antoine, Martine [1 ]
Becette, Veronique [1 ]
Bor, Catherine [1 ]
Brabencova, Eva [1 ]
Charafe-Jauffret, Emmanuelle [1 ]
Chenard, Marie-Pierre [1 ]
Dauplat, Marie-Melanie [1 ]
Delree, Paul [1 ]
Devouassoux, Mojgan [1 ]
Fiche, Maryse [1 ]
Fondrevelle, Marie-Eve [1 ]
Fridman, Viviana [1 ]
Garbar, Christian [1 ]
Genin, Pascal [1 ]
Ghnassia, Jean-Pierre [1 ]
Haudebourg, Juliette [1 ]
Laberge-Le Couteulx, Sophie [1 ]
Loussouarn, Delphine [1 ]
Maran-Gonzalez, Aurelie [1 ]
Marcy, Myriam [1 ]
Michenet, Patrick [1 ]
Sagan, Christine [1 ]
Trassard, Martine [1 ]
Verriele, Veronique [1 ]
Arnould, Laurent [1 ]
Lacroix-Triki, Magali [1 ]
机构
[1] Unicancer, Grp Etud Facteurs Pronost Immunohistochim Canc Se, F-75654 Paris 13, France
关键词
HER2; Breast cancer; Immunohistochemistry; Fixative; Guidelines; Biomarker; IN-SITU HYBRIDIZATION; FORMALIN FIXATION; ESTROGEN-RECEPTOR; PROGESTERONE-RECEPTOR; IMMUNOHISTOCHEMISTRY; TISSUE; TIME; HER2; PRESERVATION; DELAY;
D O I
10.1016/j.annpat.2014.08.017
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Biomarker assessment of breast cancer tumor samples is part of the routine workflow of pathology laboratories. International guidelines have recently been updated, with special regards to the pre-analytical steps that are critical for the quality of immunohistochemical and in situ hybridization procedures, whatever the biomarker analyzed. Fixation and specimen handling protocols must be standardized, validated and carefully tracked. Cooperation and training of the personnel involved in the specimen workflow (e.g. radiologists, surgeons, nurses, technicians and pathologists) are of paramount importance. The GEFPICS' update of the recommendations herein details and comments the different steps of the pre-analytical process. Application of these guidelines and participation to quality insurance programs are mandatory to ensure the correct evaluation of oncotheranostic biomarkers. (C) 2014 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:366 / 372
页数:7
相关论文
共 25 条
  • [1] 2021 update of the GEFPICS' recommendations for HER2 status assessment in invasive breast cancer in France
    Franchet, Camille
    Djerroudi, Lounes
    Maran-Gonzalez, Aurelie
    Abramovici, Olivia
    Antoine, Martine
    Becette, Veronique
    Berghian, Anca
    Blanc-Fournier, Cecile
    Brabencova, Eva
    Charafe-Jauffret, Emmanuelle
    Chenard, Marie-Pierre
    Dauplat, Marie-Melanie
    Delree, Paul
    Duprez-Paumier, Raphaelle
    Fleury, Clemence
    Ghnassia, Jean-Pierre
    Haudebourg, Juliette
    Leroux, Agnes
    MacGrogan, Gaetan
    Mathieu, Marie-Christine
    Michenet, Patrick
    Penault-Llorca, Frederique
    Poulet, Bruno
    Robin, Yves Marie
    Roger, Pascal
    Russ, Elisabeth
    Tixier, Lucie
    Treilleux, Isabelle
    Valent, Alexander
    Verriele, Veronique
    Vincent-Salomon, Anne
    Arnould, Laurent
    Lacroix-Triki, Magali
    [J]. ANNALES DE PATHOLOGIE, 2021, 41 (06) : 507 - 520
  • [2] 2014 update of the GEFPICS' recommendations for HER2 status determination in breast cancers in France
    Penault-Llorca, Frederique
    Vincent-Salomon, Anne
    MacGrogan, Gaetan
    Roger, Pascal
    Treilleux, Isabelle
    Valent, Alexander
    Mathieu, Marie-Christine
    Antoine, Martine
    Becette, Veronique
    Bor, Catherine
    Brabencova, Eva
    Charafe-Jauffret, Emmanuelle
    Chenard, Marie-Pierre
    Dauplat, Marie-Melanie
    Delree, Paul
    Devouassoux, Mojgan
    Fiche, Maryse
    Fondrevelle, Marie-Eve
    Fridman, Viviana
    Garbar, Christian
    Genin, Pascal
    Ghnassia, Jean-Pierre
    Haudebourg, Juliette
    Laberge-Le Couteulx, Sophie
    Loussouarn, Delphine
    Maran-Gonzalez, Aurelie
    Marcy, Myriam
    Michenet, Patrick
    Poulet, Bruno
    Sagan, Christine
    Trassard, Martine
    Verriele, Veronique
    Arnould, Laurent
    Lacroix-Triki, Magali
    [J]. ANNALES DE PATHOLOGIE, 2014, 34 (05) : 352 - 365
  • [3] Study of Pre-analytical effects on Breast Cancer Biomarkers
    Molina, Mariel
    Jain, Pragya Virendrakumar
    Cortina, Chandler
    Schneider, Ellen
    Sun, Yunguang
    Rui, Hallgeir
    Jorns, Julie
    [J]. LABORATORY INVESTIGATION, 2023, 103 (03) : S181 - S182
  • [4] Pre-analytical setting is critical for an assessment of the Ki-67 labeling index for breast cancer
    Arima, N.
    Toyozumi, Y.
    Nishimura, R.
    Osako, T.
    Nishiyama, Y.
    Nakano, M.
    Fujisue, M.
    Tashima, R.
    Moriya, T.
    [J]. CANCER RESEARCH, 2013, 73
  • [5] Urinary extracellular vesicles: Assessment of pre-analytical variables and development of a quality control with focus on transcriptomic biomarker research
    Barreiro, Karina
    Dwivedi, Om Prakash
    Valkonen, Sami
    Groop, Per-Henrik
    Tuomi, Tiinamaija
    Holthofer, Harry
    Rannikko, Antti
    Yliperttula, Marjo
    Siljander, Pia
    Laitinen, Saara
    Serkkola, Elina
    af Hallstrom, Taija
    Forsblom, Carol
    Groop, Leif
    Puhka, Maija
    [J]. JOURNAL OF EXTRACELLULAR VESICLES, 2021, 10 (12)
  • [6] Urine biomarkers in cancer detection: a systematic review of pre-analytical parameters and applied methods with focus on breast cancer
    Jordaens, S.
    Zwaenepoel, K.
    Tjalma, W.
    Deben, C.
    Beyers, K.
    Vankerckhoven, V.
    Pauwels, P.
    Vorsters, A.
    [J]. BREAST, 2023, 68 : S31 - S31
  • [7] IMPACT OF PRE-ANALYTICAL HANDLING CONDITIONS ON THE EXPRESSION OF URINARY EXTRACELLULAR VESICLE PROTEIN BIOMARKER FOR BLADDER CANCER DIAGNOSIS
    Park, Jinsung
    Lee, Jisu
    Kim, Eunha
    Park, Joohee
    Lee, Myung-Shin
    [J]. JOURNAL OF UROLOGY, 2024, 211 (05): : E229 - E230
  • [8] Impact of Recording of Pre-Analytical Specimen Handling Conditions for ER and PR Testing in Women with Breast Cancer
    Hammond, E.
    Fetzer, J.
    Belnap, T.
    Rowley, B.
    Hull, C.
    Nkoy, F.
    [J]. CANCER RESEARCH, 2009, 69 (24) : 758S - 758S
  • [9] Is serum matrix metalloproteinase 9 a useful biomarker in detection of colorectal cancer? Considering pre-analytical interference that may influence diagnostic accuracy
    K Jung
    [J]. British Journal of Cancer, 2008, 99 : 553 - 554
  • [10] Is serum matrix metalloproteinase 9 a useful biomarker in detection of colorectal cancer? Considering pre-analytical interference that may influence diagnostic accuracy
    Jung, K.
    [J]. BRITISH JOURNAL OF CANCER, 2008, 99 (03) : 553 - 554